"By demonstrating a very significant reduction in cardiovascular deaths while improving quality of life, Novartis' new heart failure medicine, LCZ696, represents one of the most important ...

The final result was anything but simple and exceeded expectations –resonating strongly with the heart failure audience and spreading awareness about a chronic ... everyday habits upon diagnosis and ...

As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...